Congrats! Great to see this from inception in 2014 to news recently that they work with Moderna to scale synthetic DNA vaccine production to global demand. I like Part Deux of their revenue stream: royalties. Taking equity stakes in spin off bio-engineered consumer products. And the best part for a biotech startup, faster regulatory approval than pharma ;)